⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TBPH News
Theravance Biopharma, Inc.
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
prnewswire.com
TBPH
TBPH ALERT: Levi & Korsinsky Investigates Theravance Biopharma, Inc. for Possible Securities Fraud Violations Ready to Announce with Confidence?
newsfilecorp.com
TBPH
Form 8-K
sec.gov
TBPH
Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions
prnewswire.com
TBPH
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025
prnewswire.com
TBPH
Theravance Biopharma to Participate in Upcoming Investor Conferences
prnewswire.com
TBPH
Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
prnewswire.com
TBPH
Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System
prnewswire.com
TBPH
Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025
prnewswire.com
TBPH
Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy
businesswire.com
TBPH